{
    "Trade/Device Name(s)": [
        "Atellica CH Amylase_2 (AMY_2)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K191454",
    "Predicate Device Reference 510(k) Number(s)": [
        "K903309"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFJ"
    ],
    "Summary Letter Date": "May 30, 2019",
    "Summary Letter Received Date": "May 31, 2019",
    "Submission Date": "May 30, 2019",
    "Regulation Number(s)": [
        "21CFR862.1070"
    ],
    "Regulation Name(s)": [
        "Amylase Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Amylase"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica CH Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic colorimetric assay",
        "Photometric method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Atellica CH Amylase_2 enzymatic colorimetric assay for quantitative determination of amylase activity in serum, plasma, and urine on Atellica CH Analyzer",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative determination of amylase activity in human serum, plasma (lithium heparin), and urine, used primarily in the diagnosis and monitoring of acute pancreatitis",
    "fda_folder": "Clinical Chemistry"
}